Peer-influenced content. Sources you trust. No registration required. This is HCN.

Oncology News Central (ONC)BMS Provides Update on CheckMate-901 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with Unresectable or Metastatic Urothelial Carcinoma

Nivolumab plus ipilimumab added to standard of care chemotherapy did not improve outcomes as 1st line therapy for unresectable or metastatic bladder cancers with PD-L1 expression > 1%.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form